Jagsonpal Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals shareholders have overwhelmingly approved a buy-back of up to 16 lakh (1.6 million) equity shares at ₹250 per share, totaling up to ₹40 crores. The resolution passed with 99.994% votes in favor (48.92 million votes) versus only 2,712 votes against out of 48.92 million valid votes cast. The e-voting period ran from March 26 to April 24, 2026, with 73.06% of total shares participating. Promoter and public categories both voted overwhelmingly in favor. The buy-back price of ₹250 represents a significant premium over the face value of ₹2 per share.
Shareholders who tender their shares in the buy-back will receive ₹250 per share, representing a substantial return of capital. This is positive for shareholders seeking liquidity at a premium price and signals management confidence in the company's financial health.